Baird Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $192

Baird maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $181 to $192.

Benzinga · 12/20/2019 14:44

Baird maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $181 to $192.